Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Massoud Arbabzadeh

Vascular & Interventional Radiology Garden Grove, CA Medical Doctor

NPI 1841245149 CMS profile 356352

12827 Harbor Blvd Ste G, Garden Grove, CA 92840

Open in the dashboard

General payments

$7,331

115 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Massoud Arbabzadeh of Garden Grove, CA is reported in the CMS Open Payments database as having received $7,331 across 115 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $988 18
2024 General $1,834 26
2023 General $3,213 38
2022 General $523 10
2021 General $90 6
2020 General $106 4
2019 General $577 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Massoud Arbabzadeh
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Massoud Arbabzadeh were reported at $988. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Massoud Arbabzadeh Vascular & Interventional Radiology median Middle half National median
2019 $577 $422 $125–$1,555 $163
2020 $106 $200 $68–$652 $114
2021 $90 $280 $99–$866 $132
2022 $523 $433 $137–$1,497 $149
2023 $3,213 $506 $152–$2,019 $160
2024 $1,834 $556 $175–$1,930 $164
2025 $988 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bard Peripheral Vascular, Inc. $2,737 34 payments
  2. Philips Electronics North America Corporation $1,961 34 payments
  3. Abbott Laboratories $883 7 payments
  4. Endologix, Inc. $553 2 payments
  5. Cook Medical LLC $435 19 payments
  6. Biotronik Inc. $292 5 payments
  7. Medtronic, Inc. $135 6 payments
  8. Amgen Inc. $123 1 payment
  9. Boston Scientific Corporation $103 2 payments
  10. Mozarc Medical US LLC $46 2 payments
  11. Other $62 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,680 99 payments
  2. Travel and Lodging $2,651 16 payments
Products named General payments · program years 2019–2025
  1. Crosser iQ $1,494 12 payments
  2. SUPERA $863 6 payments
  3. ENDOCROSS Device $553 2 payments
  4. Torus Stent Graft System $553 2 payments
  5. (BH4) IGT Devices Undivided $492 4 payments
  6. IGT D Peripheral $424 10 payments
  7. RotarexS 6 F x 135 cm $376 6 payments
  8. (9520) IGT Devices Undivided $286 1 payment
  9. (BS1) Peripheral Vascular Undivided $277 8 payments
  10. Pulsar-18 T3 $264 4 payments
  11. Other $2,069 58 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

13

Median for Interventional Radiology: 38

Drug cost

$110

Median for Interventional Radiology: $333

Branded share of claims

100%

Median for Interventional Radiology: 53%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 13 $110

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 554 Part D prescribers listed as Interventional Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$753,549

Of which drugs: $1,877

Medicare patients

391

Average age 70

Services billed

6,198

174 women, 217 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Chronic kidney disease 75%
Heart failure 59%
Ischemic heart disease 59%
Arthritis 43%
Atrial fibrillation 32%
Depression 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 34 3,820 $398

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

115 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record